Canaccord Genuity Group Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $48.00

Intellia Therapeutics (NASDAQ:NTLA) had its price target cut by Canaccord Genuity Group from $54.00 to $48.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts also recently weighed in on the company. Wolfe Research reaffirmed a “peer perform” rating on shares of Intellia Therapeutics in a research note on Wednesday, November 12th. JPMorgan Chase & Co. restated an “underweight” rating and issued a $5.00 price target (down from $12.00) on shares of Intellia Therapeutics in a research report on Friday, November 7th. William Blair raised Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday. JonesTrading lowered shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Finally, Wells Fargo & Company raised their target price on shares of Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Tuesday. Eleven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $19.59.

Intellia Therapeutics Stock Down 4.8%

Shares of NASDAQ NTLA opened at $13.15 on Tuesday. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -3.43 and a beta of 2.10. Intellia Therapeutics has a 52 week low of $5.90 and a 52 week high of $28.25. The firm has a 50-day moving average price of $12.25 and a 200 day moving average price of $13.10.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The company had revenue of $23.02 million for the quarter, compared to analyst estimates of $12.17 million. During the same period in the prior year, the business posted ($1.27) earnings per share. The firm’s revenue for the quarter was up 78.4% compared to the same quarter last year. Equities research analysts expect that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In related news, EVP Birgit C. Schultes sold 8,508 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the transaction, the executive vice president owned 98,533 shares of the company’s stock, valued at approximately $907,488.93. This represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP James Basta sold 10,397 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $95,756.37. Following the sale, the executive vice president owned 101,528 shares in the company, valued at approximately $935,072.88. This trade represents a 9.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 53,051 shares of company stock worth $488,600. Corporate insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of NTLA. Virtu Financial LLC acquired a new stake in shares of Intellia Therapeutics during the fourth quarter worth $245,000. Invesco Ltd. boosted its stake in Intellia Therapeutics by 5.8% in the 4th quarter. Invesco Ltd. now owns 433,290 shares of the company’s stock worth $3,895,000 after buying an additional 23,870 shares during the last quarter. Axxcess Wealth Management LLC boosted its stake in Intellia Therapeutics by 20.1% in the 4th quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company’s stock worth $192,000 after buying an additional 3,583 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in Intellia Therapeutics in the 4th quarter valued at about $90,000. Finally, XTX Topco Ltd purchased a new stake in Intellia Therapeutics in the 4th quarter valued at about $402,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Key Intellia Therapeutics News

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds on a second gene?therapy trial for Intellia — a material de?risking event that restores clinical momentum for NTLA’s in?vivo programs and was a direct catalyst for recent rallies. FDA’s lifting of clinical holds sends Intellia upwards
• Positive Sentiment: Multiple analyst upgrades and bullish notes — JonesTrading upgraded NTLA to Buy with a $29 target (large upside), and other firms (Leerink, Wells Fargo) issued bullish commentary that supports higher near?term sentiment. JonesTrading upgrade / coverage summary
• Positive Sentiment: Royal Bank of Canada raised its price target to $15, reinforcing analyst support after the recent rebound. RBC boosts Intellia price target to $15
• Neutral Sentiment: HC Wainwright slightly trimmed near?term EPS estimates but kept a Buy rating and a $30 target — a mixed signal (modest near?term cost pressure acknowledged, long?term conviction intact). HC Wainwright analyst note
• Neutral Sentiment: Valuation discussion: recent recovery has put NTLA back on investors’ radar but analysts note wide losses and heavy R&D spending; the stock’s rebound raises valuation questions for some investors. A Look At Intellia Therapeutics Valuation
• Negative Sentiment: Canaccord lowered expectations for NTLA — an analyst downgrade to forecasts that can weigh on near?term sentiment and give holders a reason to take profits after the run?up. Canaccord lowers expectations

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.